Neurocrine Biosciences (LTS:0K6R) Change In Payables And Accrued Expense : $60 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Neurocrine Biosciences Change In Payables And Accrued Expense?

Neurocrine Biosciences's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $12 Mil. It means Neurocrine Biosciences's Accounts Payable & Accrued Expense increased by $12 Mil from Dec. 2024 to Mar. 2025 .

Neurocrine Biosciences's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $29 Mil. It means Neurocrine Biosciences's Accounts Payable & Accrued Expense increased by $29 Mil from Dec. 2023 to Dec. 2024 .

Neurocrine Biosciences Change In Payables And Accrued Expense Historical Data

The historical data trend for Neurocrine Biosciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Change In Payables And Accrued Expense Chart

Neurocrine Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

26.90

56.80

114.60

64.30

29.00

Neurocrine Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-18.60	-59.50	39.40	67.70	12.40

Neurocrine Biosciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $60 Mil.

Neurocrine Biosciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (LTS:0K6R) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NBIX:USA 1NBIX:Italy NB3:Germany N1BI34:Brazil

Address

6027 Edgewood Bend Court, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines